15 Feb Madison-made skin tissue ExpressGraft begins human tests to treat diabetic foot ulcers
A second wound-healing skin tissue developed in Madison has begun tests on human patients.
ExpressGraft-C9T1 is being used in first-round tests on a patient with diabetic foot ulcers — open sores that can affect patients with diabetes and can lead to amputation, said Mallinckrodt, the global pharmaceutical company whose Madison division, formerly Stratatech Corp., developed the tissue.
“Diabetic foot ulcers and resulting complications can be physically debilitating and lead to emotionally devastating problems in this population,” said Thomas Serena, CEO and medical director of SerenaGroup, of Hingham, Massachusetts, and lead investigator on the study, which is being conducted in Pittsburgh.
ExpressGraft-C9T1 is a genetically engineered, antimicrobial human skin substitute. It may benefit patients with “chronic, difficult-to-heal wounds such as those seen in patients with diabetes,” said Lynn Allen-Hoffmann, who was the founder and CEO of Stratatech and now is senior vice president of regenerative medicine at Mallinckrodt.
Sorry, the comment form is closed at this time.